Phase III and VI pain trials
C4Pain has the capability to perform large phase III and phase IV trails including extensions of phase II trials in order to meet what ever regulatory requests from the FDA or EMEA concerning efficacy and safety and in the future which pain mechanisms are involved.
From a mechanism based perspective it is an advantage to include pain bio-markers in clinical studies together with the traditional clinical pain scores as such measures often are more sensitive than simple clinical pain measures and provide a valuable additional mechanistic understanding of the drug action.